Hubei Jianxiang Bioscience: difference between revisions
Diff·revision 23 → 24·07:41, 5 Aug 2025
Difference between revision 23 and revision 24 of Hubei Jianxiang Bioscience. 2 lines changed; the page grew by 360 bytes.
| Revision 23 — 06:38, 29 Jul 2025 PrimarySrcPatia (talk) add DOI 6,978 bytes ±0 | Revision 24 — 07:41, 5 Aug 2025 CheckSumChase (talk) clarify whether figure is gross or net mass 7,338 bytes +360 | ||
|---|---|---|---|
| 52 | Submitted reports on HJ material to July 2026 are concentrated on the incretin analogues, with reported [[Area percent purity|area percent]] figures clustering in the high nineties and, where a water figure accompanied them, purchaser-computed [[Peptide content|peptide content]] in the low-to-mid eighties by mass.{{r|reports,usp1503}} | 52 | Submitted reports on HJ material to July 2026 are concentrated on the incretin analogues, with reported [[Area percent purity|area percent]] figures clustering in the high nineties and, where a water figure accompanied them, purchaser-computed [[Peptide content|peptide content]] in the low-to-mid eighties by mass.{{r|reports,usp1503}} |
| 53 | 53 | ||
| + | 54 | A peptide content in the low eighties is not a deficiency: for a lyophilised peptide with a trifluoroacetate counterion and several percent water it is the arithmetically expected figure. It is stated because readers who see a purity figure of 99% and a content figure of 83% on the same certificate frequently take the discrepancy for an error.{{r|usp1503}} | |
| + | 55 | ||
| 54 | == References == | 56 | == References == |
| 55 | {{reflist}} | 57 | {{reflist}} |